Protein / target
Fibroblast growth factor receptor 2
Protein at a glance
Biological role
Fibroblast growth factor receptor
Primary biology
FGFR growth-factor signalling
Strongest disease association
Pfeiffer syndrome
Therapeutic position
Established drug target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development.
View complete UniProt function annotationHide complete annotation
Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1
Subcellular location
Domains and Gene Ontology detail (117)Hide
Domains & features
Gene Ontology
- Ccell cortex
- Ccell surface
- Ccytoplasm
- Ccytoplasmic vesicle
- Cexcitatory synapse
- Cextracellular region
- CGolgi apparatus
- Cmembrane
- Cnucleus
- Cplasma membrane
- Creceptor complex
- FATP binding
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Cell proliferation & survival
- ·Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth facto…
- ·fibroblast growth factor receptor signaling pathway involved in positive regulation of c…
- ·positive regulation of cell population proliferation
- ·PIP3 activates AKT signaling
Growth-factor signalling
- ·Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth facto…
- ·fibroblast growth factor binding
- ·fibroblast growth factor receptor activity
- ·fibroblast growth factor receptor signaling pathway
Oncogenic signalling
- ·Constitutive Signaling by Aberrant PI3K in Cancer
Kinase signalling
- ·Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth facto…
- ·protein tyrosine kinase activity
Transcriptional regulation
- ·negative regulation of transcription by RNA polymerase II
- ·positive regulation of transcription by RNA polymerase II
Apoptosis & cell death
- ·apoptotic process
- ·fibroblast growth factor receptor signaling pathway involved in negative regulation of a…
View underlying pathways (17)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Broader indication categories (1)Hide
Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.
11 medicines meet Open Targets' target-level approved-medicine definition; the 4 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Fibroblast growth factor receptor 2 inhibitor
Fibroblast growth factor receptor 2 inhibitor
Indicated for Cholangiocarcinoma, Neoplasms
Fibroblast growth factor receptor 2 inhibitor
Indicated for Colorectal Neoplasms, Neoplasms
Fibroblast growth factor receptor inhibitor
Indicated for Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasms
Fibroblast growth factor receptor inhibitor
Indicated for Cholangiocarcinoma, Neoplasms
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene FGFR2
Gene-level evidence surfaced through the gene FGFR2that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
27 compounds recorded · 11 approved · 16 in clinical development
View all recorded compounds (10)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Strong
Antibodies — Strong
Protein degraders — Emerging
Other modalities — Strong
View underlying tractability evidence (15)Hide
Raw Open Targets tractability assessment buckets, by modality.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 5 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Trial status changed
A Phase 1b/2 Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetics of Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer (FORTITUDE-103).
- Regulatory approval
Approval: Balversa (EMA)
- New publicationLenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.
- New publicationBemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.
- Regulatory approval
Approval: Lytgobi (EMA)
- New publicationFutibatinib for <i>FGFR2</i>-Rearranged Intrahepatic Cholangiocarcinoma.
- Regulatory approval
Approval: Pemazyre (EMA)
- New publicationTargeted therapy for hepatocellular carcinoma.
- New publicationErdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
- New publicationRandomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.
- New publicationRegorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
- Regulatory approval
Approval: Stivarga (EMA)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.